
ExpreS²ion publishes video from COVID-19-focused company presentation at Japanese event

ExpreS²ion Biotech Holding AB's affiliate ExpreS²ion Biotechnologies ApS ("ExpreS²ion") announces that a filmed company presentation with CEO Bent U. Frandsen at a digital event in Japan, hosted by the Royal Danish Embassy in Tokyo and Healthcare Denmark, has been published on the company's website.

The presentation was held on September 29, 2020 and had a special focus on the development of ExpreS²ion's COVID-19 vaccine. The COVID-19 vaccine is licensed to Bavarian Nordic, with a clinical program expected to be completed in 2021.

This and other recent company presentations can be found on the [presentation page of ExpreS²ion's website](#).

Certified Adviser

Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se

For further information about ExpreS²ion Biotech Holding AB, please contact:

Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com

About ExpreS²ion

ExpreS²ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS²ion Biotech Holding AB with company register number 559033-3729. ExpreS²ion has developed a unique technology platform, ExpreS², for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS² is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. Since 2017, ExpreS²ion develops novel VLP based vaccines through its joint venture AdaptVac ApS. For additional information, please visit www.expres2ionbio.com and www.adaptvac.com.